{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:38:51Z","timestamp":1779230331325,"version":"3.51.4"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>A significant subset of well-differentiated prostatic acinar neoplasms with invasive histologic features will not spread outside of the prostate, become symptomatic, or shorten a patient\u2019s life even if the tumor is left untreated. Overdiagnosis and overtreatment of these indolent prostate cancers (PCa) remain a significant health care problem despite the improved risk assessment and uptake in acceptance of conservative management. While detection of indolent PCa on an entirely resected prostate is possible, recognition of indolent PCa on a needle biopsy (NBX) cannot be reliably made as Grade Group 1 (GG1) PCa diagnosis on NBX is not always identical to one from radical prostatectomy due to a variety of reasons. Further, some of the initially diagnosed GG1 PCas on NBX and carefully monitored on active surveillance (AS) are later reclassified with higher grades. At the same time, other GG1 PCas never progressed on long-term follow-up while receiving no therapy. The overarching goal of this white paper by the 2 leading uropathology organizations, Genitourinary Pathology Society (GUPS) and International Society of Urological Pathology (ISUP), is to help identify a path toward a more meaningful multidisciplinary solution addressing the pervasive problem of overdiagnosis of indolent PCa and its downstream negative effects. Herein, GUPS and ISUP jointly release statements that address why recognition of indolent PCa cannot be reliably made in NBX and why various contemporary multidisciplinary approaches are needed to help improve the detection of indolent PCa in NBX.<\/jats:p>","DOI":"10.1097\/pas.0000000000002425","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T09:05:59Z","timestamp":1748595959000},"page":"e27-e32","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer"],"prefix":"10.1097","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0820-6823","authenticated-orcid":false,"given":"Rajal B.","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Anatomic Pathology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladell P.","family":"Paner","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Surgery (Urology), University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Alpert Medical School of Brown University, Providence, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo M.","family":"De Marzo","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Magi-Galluzzi","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali","family":"Varma","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, University Hospital of Wales, Cardiff"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mount Sinai School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Alpert Medical School of Brown University, Providence, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahul B.","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Tennessee Health Science System, Memphis, TN"},{"name":"Urology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju","family":"Aron","sequence":"additional","affiliation":[{"name":"Pathology and Urology, USC Keck School of Medicine, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela W.","family":"Cunha","sequence":"additional","affiliation":[{"name":"D\u2019Or Institute for Research and Education (IDOR) and\u00a0Department of Pathology, Rede D\u2019Or\/Sao Luiz Hospital,\u00a0Sao Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan I.","family":"Epstein","sequence":"additional","affiliation":[{"name":"Integrate Medical Professionals Pathology, Garden City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samson W.","family":"Fine","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiman","family":"Haider","sequence":"additional","affiliation":[{"name":"Department of Pathology, University College London Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A.","family":"Iczkowski","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California \u2013 Davis Health, Sacramento, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Kench","sequence":"additional","affiliation":[{"name":"Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi P.","family":"Kunju","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sambit K.","family":"Mohanty","sequence":"additional","affiliation":[{"name":"Department of Pathology, CORE Diagnostics, Gurgaon, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Montironi","sequence":"additional","affiliation":[{"name":"Molecular Medicine and Cell Therapy Foundation, c\/o Polytechnic, University of the Marche Region, Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Netto","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Chen","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Srigley","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puay Hoon","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Luma Medical Center, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University, Nagakute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodorus H.","family":"van der Kwast","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert J.","family":"van Leenders","sequence":"additional","affiliation":[{"name":"Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"R1-20251112","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"key":"R2-20251112","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-grade prostate cancer: time to stop calling it cancer","volume":"40","author":"Eggener","year":"2022","journal-title":"J Clin Oncol"},{"key":"R3-20251112","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1200\/JCO.22.00926","article-title":"Renaming Gleason score 6 prostate to noncancer: a flawed idea scientifically and for patient care","volume":"40","author":"Epstein","year":"2022","journal-title":"J Clin Oncol"},{"key":"R4-20251112","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eururo.2022.09.015","article-title":"Prostate adenocarcinoma grade group 1: rationale for retaining a cancer label in the 2022 World Health Organization Classification","volume":"83","author":"Netto","year":"2023","journal-title":"Eur Urol"},{"key":"R5-20251112","doi-asserted-by":"crossref","DOI":"10.1097\/PAP.0000000000000400","article-title":"Renaming grade group 1 prostate \u201cCancer\u201d from a pathology perspective: a call for multidisciplinary discussion","author":"Paner","year":"2023","journal-title":"Adv Anat Pathol"},{"key":"R6-20251112","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/JU.0000000000003510","article-title":"Point-counterpoint: Gleason score 6\/Grade group 1 prostate cancer should be renamed as \u201cnon-cancer\u201d to improve public health: a wrong idea from a pathologist\u2019s perspective","volume":"210","author":"Shah","year":"2023","journal-title":"J Urol"},{"key":"R7-20251112","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.urolonc.2022.09.028","article-title":"Should grade group 1 prostate cancer be reclassified as \u201cnon-cancer\u201d? A pathology community perspective","volume":"41","author":"Zhou","year":"2023","journal-title":"Urol Oncol"},{"key":"R8-20251112","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/JU.0000000000003511","article-title":"Point-counterpoint: grade group 1 (Gleason score 6) prostate cancer should be renamed to improve public health: pathologists\u2019 perspective","volume":"210","author":"Zhou","year":"2023","journal-title":"J Urol"},{"key":"R9-20251112","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bju.12879","article-title":"Disease-specific death and metastasis do not occur in patients with Gleason score <\/=6 at radical prostatectomy","volume":"116","author":"Kweldam","year":"2015","journal-title":"BJU Int"},{"key":"R10-20251112","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","article-title":"Do adenocarcinomas of the prostate with Gleason score (GS) <\/=6 have the potential to metastasize to lymph nodes?","volume":"36","author":"Ross","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R11-20251112","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2016.11.028","article-title":"Extraprostatic extension is extremely rare for contemporary Gleason score 6 prostate cancer","volume":"72","author":"Anderson","year":"2017","journal-title":"Eur Urol"},{"key":"R12-20251112","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.juro.2017.11.067","article-title":"Incidence of extraprostatic extension at radical prostatectomy with pure Gleason score 3 + 3 = 6 (Grade Group 1) cancer: implications for whether Gleason score 6 prostate cancer should be renamed \u201cnot cancer\u201d and for selection criteria for active surveillance","volume":"199","author":"Hassan","year":"2018","journal-title":"J Urol"},{"key":"R13-20251112","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.urology.2018.07.028","article-title":"Temporal trend in incidental prostate cancer detection at surgery for benign prostatic hyperplasia","volume":"122","author":"Capogrosso","year":"2018","journal-title":"Urology"},{"key":"R14-20251112","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1309\/AJCP4OCYZBAN9TJU","article-title":"Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant?","volume":"131","author":"Mazzucchelli","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"R15-20251112","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.humpath.2005.03.018","article-title":"Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens","volume":"36","author":"Montironi","year":"2005","journal-title":"Hum Pathol"},{"key":"R16-20251112","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer","volume":"271","author":"Epstein","year":"1994","journal-title":"JAMA"},{"key":"R17-20251112","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0022-5347(17)42864-3","article-title":"Unsuspected prostatic adenocarcinoma in patients who have undergone radical cystoprostatectomy for transitional cell carcinoma of the bladder","volume":"139","author":"Pritchett","year":"1988","journal-title":"J Urol"},{"key":"R18-20251112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.juro.2010.08.082","article-title":"A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial","volume":"185","author":"Wolters","year":"2011","journal-title":"J Urol"},{"key":"R19-20251112","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/pcan.2010.16","article-title":"Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy","volume":"14","author":"Karavitakis","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R20-20251112","doi-asserted-by":"crossref","first-page":"452 e1","DOI":"10.1016\/j.urolonc.2022.07.012","article-title":"Sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (Cribriform Gleason pattern 4 and intraductal carcinoma): correlation of detected and missed prostate cancer foci with whole mount histopathology","volume":"40","author":"Cai","year":"2022","journal-title":"Urol Oncol"},{"key":"R21-20251112","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N Engl J Med"},{"key":"R22-20251112","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.eururo.2019.09.005","article-title":"The key combined value of multiparametric magnetic resonance imaging, and magnetic resonance imaging-targeted and concomitant systematic biopsies for the prediction of adverse pathological features in prostate cancer patients undergoing radical prostatectomy","volume":"77","author":"Gandaglia","year":"2020","journal-title":"Eur Urol"},{"key":"R23-20251112","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eururo.2020.06.041","article-title":"Serial molecular profiling of low-grade prostate cancer to assess tumor upgrading: a longitudinal cohort study","volume":"79","author":"Salami","year":"2021","journal-title":"Eur Urol"},{"key":"R24-20251112","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/sim.6003","article-title":"Modeling grade progression in an active surveillance study","volume":"33","author":"Inoue","year":"2014","journal-title":"Stat Med"},{"key":"R25-20251112","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cell.2018.03.029","article-title":"The evolutionary landscape of localized prostate cancers drives clinical aggression","volume":"173","author":"Espiritu","year":"2018","journal-title":"Cell"},{"key":"R26-20251112","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.ju.0000070928.49986.04","article-title":"Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers","volume":"170","author":"Noguchi","year":"2003","journal-title":"J Urol"},{"key":"R27-20251112","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1200\/JCO.2013.50.3540","article-title":"Diagnostic challenges of clonal heterogeneity in prostate cancer","volume":"33","author":"Haffner","year":"2015","journal-title":"J Clin Oncol"},{"key":"R28-20251112","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.euo.2023.10.005","article-title":"Outcomes of biopsy grade group 1 prostate cancer diagnosis in the Danish population","volume":"7","author":"Stroomberg","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"R29-20251112","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00428-020-02858-w","article-title":"Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence-assisted grading","volume":"477","author":"Egevad","year":"2020","journal-title":"Virchows Arch"},{"key":"R30-20251112","first-page":"3990","article-title":"Diagnosis of \u201ccribriform\u201d prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations","volume":"11","author":"Shah","year":"2021","journal-title":"Am J Cancer Res"},{"key":"R31-20251112","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/PAS.0000000000000457","article-title":"Diagnosis of \u201cPoorly Formed Glands\u201d, Gleason pattern 4 prostatic adenocarcinoma on needle biopsy: an interobserver reproducibility study among urologic pathologists with recommendations","volume":"39","author":"Zhou","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R32-20251112","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/his.12976","article-title":"Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists","volume":"69","author":"Kweldam","year":"2016","journal-title":"Histopathology"},{"key":"R33-20251112","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.humpath.2016.06.009","article-title":"Improvement of diagnostic agreement among pathologists in resolving an \u201catypical glands suspicious for cancer\u201d diagnosis in prostate biopsies using a novel \u201cDisease-Focused Diagnostic Review\u201d quality improvement process","volume":"56","author":"Shah","year":"2016","journal-title":"Hum Pathol"},{"key":"R34-20251112","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"R35-20251112","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1158\/1078-0432.CCR-08-2927","article-title":"Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States","volume":"15","author":"Mosquera","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R36-20251112","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/modpathol.2016.63","article-title":"PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance","volume":"29","author":"Trock","year":"2016","journal-title":"Mod Pathol"},{"key":"R37-20251112","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.euf.2017.03.004","article-title":"PTEN Loss but not ERG expression in diagnostic biopsies is associated with increased risk of progression and adverse surgical findings in men with prostate cancer on active surveillance","volume":"4","author":"Lokman","year":"2018","journal-title":"Eur Urol Focus"},{"key":"R38-20251112","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"key":"R39-20251112","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/modpathol.2014.85","article-title":"PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy","volume":"28","author":"Lotan","year":"2015","journal-title":"Mod Pathol"},{"key":"R40-20251112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11934-017-0724-5","article-title":"African-American prostate cancer disparities","volume":"18","author":"Smith","year":"2017","journal-title":"Curr Urol Rep"},{"key":"R41-20251112","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1158\/1055-9965.EPI-12-1238","article-title":"Genes associated with prostate cancer are differentially expressed in African American and European American men","volume":"22","author":"Powell","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R42-20251112","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.eururo.2019.01.010","article-title":"Prostate cancer genomic-risk differences between African-American and White men across Gleason scores","volume":"75","author":"Mahal","year":"2019","journal-title":"Eur Urol"},{"key":"R43-20251112","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/01.ju.0000169134.28610.66","article-title":"Preoperative prediction of small volume cancer (less than 0.5 mL) in radical prostatectomy specimens","volume":"174","author":"Cheng","year":"2005","journal-title":"J Urol"},{"key":"R44-20251112","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/PAP.0000000000000192","article-title":"Unfavorable pathology, tissue biomarkers and genomic tests with clinical implications in prostate cancer management","volume":"25","author":"Nguyen","year":"2018","journal-title":"Adv Anat Pathol"},{"key":"R45-20251112","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/his.15231","article-title":"Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage","volume":"85","author":"Nguyen","year":"2024","journal-title":"Histopathology"},{"key":"R46-20251112","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","article-title":"Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance","volume":"29","author":"Porten","year":"2011","journal-title":"J Clin Oncol"},{"key":"R47-20251112","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"key":"R48-20251112","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/JU.0000000000003461","article-title":"Identifying men who can remain on active surveillance despite biopsy reclassification to grade group 2 prostate cancer","volume":"210","author":"Baraban","year":"2023","journal-title":"J Urol"},{"key":"R49-20251112","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","article-title":"Targeted prostate biopsy: umbra, penumbra, and value of perilesional sampling","volume":"82","author":"Brisbane","year":"2022","journal-title":"Eur Urol"},{"key":"R50-20251112","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1158\/0008-5472.CAN-07-2043","article-title":"Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases","volume":"67","author":"Mehra","year":"2007","journal-title":"Cancer Res"},{"key":"R51-20251112","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13059-016-1129-3","article-title":"Identifying aggressive prostate cancer foci using a DNA methylation classifier","volume":"18","author":"Mundbjerg","year":"2017","journal-title":"Genome Biol"},{"key":"R52-20251112","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.19.02768","article-title":"Molecular biomarkers in localized prostate cancer: ASCO guideline","volume":"38","author":"Eggener","year":"2020","journal-title":"J Clin Oncol"},{"key":"R53-20251112","doi-asserted-by":"crossref","first-page":"e2400269","DOI":"10.1200\/PO.24.00269","article-title":"A targeted methylation-based multicancer early detection blood test preferentially detects high-grade prostate cancer while minimizing overdiagnosis of indolent disease","volume":"8","author":"Mahal","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"R54-20251112","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:00:40Z","timestamp":1762927240000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002425","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}